Pegaspargase

CHEMBL2108546 Phase 4 Đã phê duyệt Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This enzyme-based cancer medication treats acute lymphoblastic leukemia by depleting asparagine that leukemia cells need.

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This enzyme-based cancer medication treats acute lymphoblastic leukemia by depleting asparagine that leukemia cells need.

Yes, Pegaspargase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108546. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.